About: Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01
Creator	Apetrei, Cristian Baghian, Abolghasem Pahar, Bapi Wakamatsu, Nobuko Iyer, Arun Chouljenko, Vladimir Kousoulas, Konstantin Marx, Preston Boudreaux, Marc Roy, Alma
Source	Elsevier; Medline; PMC
abstract	Abstract Vesicular stomatitis virus (VSV) has been extensively utilized as a viral vector system for the induction of protective immune responses against a variety of pathogens. We constructed recombinant VSVs specifying either the Indiana or Chandipura virus G glycoprotein and expressing the West Nile virus (WNV) envelope (E) glycoprotein. Mice were intranasally vaccinated using a prime (Indiana)-boost (Chandipura) immunization approach and challenged with the virulent WNV-LSU-AR01. Ninety-percent (9 of 10) of the vaccinated mice survived as compared to 10% of the mock-vaccinated mice after WNV lethal challenge. Histopathological examination of brain tissues revealed neuronal necrosis in mock-vaccinated mice but not in vaccinated mice, and vaccinated, but not mock-vaccinated mice developed a strong neutralizing antibody response against WNV. Extensive immunological analysis using polychromatic flow cytometry staining revealed that vaccinated, but not mock-vaccinated mice developed robust cellular immune responses as evidenced by up-regulation of CD4+ CD154+ IFNγ+ T cells in vaccinated, but not mock-vaccinated mice. Similarly, vaccinated mice developed robust E-glycoprotein-specific CD8+ T cell immune responses as evidenced by the presence of a high percentage of CD8+ CD62Llow IFNγ+ cells. In addition, a sizeable population of CD8+ CD69+ cells was detected indicating E-specific activation of mature T cells and CD4+ CD25+ CD127low T regulatory (T reg) cells were down-regulated. These results suggest that VSV-vectored vaccines administered intranasally can efficiently induce protective humoral and cellular immune responses against WNV infections.
has issue date	2009-02-05(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2008.11.087
bibo:pmid	19070640
has license	els-covid
sha1sum (hex)	fb080f850b4fb6c67d192394ad477d7b77c9270a
schema:url	https://doi.org/10.1016/j.vaccine.2008.11.087
resource representing a document's title	Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01
has PubMed Central identifier	PMC7115407
has PubMed identifier	19070640
schema:publication	Vaccine
resource representing a document's body	covid:fb080f850b4fb6c67d192394ad477d7b77c9270a#body_text
is schema:about of	named entity 'mice' named entity 'developed' named entity 'immunization' named entity 'neutralizing antibody' named entity 'mice' named entity 'mature' named entity 'CD8' named entity 'vaccinated' named entity 'vaccinated' named entity 'virus strain' named entity 'Nile' named entity 'BASED' named entity 'G GLYCOPROTEIN' named entity 'PRIME' named entity 'ADDITION' named entity '90%' named entity 'CD62L' named entity 'INDIANA' named entity 'HIGH PERCENTAGE' named entity 'IMMUNIZATION' named entity 'CELLS' named entity 'CHANDIPURA VIRUS' named entity 'CHALLENGE' named entity 'APPROACH' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'NEUTRALIZING ANTIBODY' named entity 'LETHAL' named entity 'PATHOGENS' named entity 'IMMUNOLOGICAL' named entity 'VECTORED' named entity 'PERCENT' named entity 'ANTIBODY RESPONSE' named entity 'INDUCTION' named entity 'DOWN-REGULATED' named entity 'SPECIFYING' named entity 'EITHER' covid:arg/fb080f850b4fb6c67d192394ad477d7b77c9270a named entity 'CHALLENGE' named entity 'VIRULENT' named entity 'RECOMBINANT' named entity 'VACCINES' named entity 'WNV INFECTIONS' named entity 'NECROSIS' named entity 'T CELLS' named entity 'POLYCHROMATIC' named entity 'BRAIN TISSUES' named entity 'POPULATION' named entity 'STAINING' named entity 'BOOST' named entity 'CD69' named entity '10%' named entity 'RECOMBINANT' named entity 'CD25' named entity 'USING' named entity 'CONSTRUCTED' named entity 'IMMUNE RESPONSES' named entity 'CD127' named entity 'ANALYSIS' named entity 'CD154' named entity 'WNV' named entity 'MATURE' named entity 'T CELL' named entity 'CELLULAR' named entity 'LETHAL' named entity 'ROBUST' named entity 'ENVELOPE' named entity 'EXTENSIVE' named entity 'IMMUNE RESPONSES' named entity 'MICE' named entity 'CELLULAR' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'VACCINE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software